Literature DB >> 10900359

Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.

V Ozenci1, M Kouwenhoven, N Teleshova, M Pashenkov, S Fredrikson, H Link.   

Abstract

Interferon-beta (IFN-beta) has a beneficial influence on the course of multiple sclerosis (MS) and has become standard treatment of this disease, though its mechanisms of action are incompletely understood. This study examines the effect of IFN-beta treatment on the cytokines IL-6, TNF-alpha, IFN-gamma and IL-10; the metalloproteinases MMP-3, -7 and -9 and the tissue inhibitor of metalloproteinase-1 (TIMP-1). IFN-beta treatment resulted in decreased numbers of mononuclear cells (MNC) secreting IL-6 and TNF-alpha and expressing mRNA of MMP-3 and MMP-9 compared to pretreatment levels. On the contrary, numbers of IL-10 secreting MNC and TIMP-1 mRNA expressing were augmented during IFN-beta therapy. Whether the down-regulatory effects on pro-inflammatory and upregulatory effects on anti-inflammatory molecules are a direct result of IFN-beta on the immune system or secondary to clinical stabilization of MS pathology induced by IFN-beta remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900359     DOI: 10.1016/s0165-5728(00)00281-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection.

Authors:  Jiehao Zhou; Stephen A Stohlman; Roscoe Atkinson; David R Hinton; Norman W Marten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

2.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

3.  Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis.

Authors:  P T Nygårdas; A E Hinkkanen
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.

Authors:  T Kanesaka; M Mori; T Hattori; T Oki; S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

5.  Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Authors:  Yvonne Benešová; Aleš Tvaroh
Journal:  Ther Adv Neurol Disord       Date:  2016-10-21       Impact factor: 6.570

6.  Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis.

Authors:  Jian Hong; Haiyan Li; Meiyue Chen; Ying C Q Zang; Sheri M Skinner; James M Killian; Jingwu Z Zhang
Journal:  Int Immunol       Date:  2009-10-11       Impact factor: 4.823

Review 7.  The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas.

Authors:  Helen Könnecke; Ingo Bechmann
Journal:  Clin Dev Immunol       Date:  2013-08-14

Review 8.  Matrix metalloproteinases in autism spectrum disorders.

Authors:  Morsi W Abdallah; Tanja M Michel
Journal:  J Mol Psychiatry       Date:  2013-09-17

9.  Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.

Authors:  Svantje Tauber; Katrin Paulsen; Susanne Wolf; Peggy Synwoldt; Andreas Pahl; Regine Schneider-Stock; Oliver Ullrich
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

Review 10.  Current and future therapies for multiple sclerosis.

Authors:  Alireza Minagar
Journal:  Scientifica (Cairo)       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.